Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD-OS in Dravet and Lennox-Gastaut Syndrome
NCT04611438Phase 3Unknown
- Sponsor
- Yonsei University
- Start
- Mar 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome (LGS), sponsored by Yonsei University. Primary endpoints: Development assessment at 24 weeks and Seizure outcome at 24 weeks. Status: unknown.
02
Drugs
cannabidiol
03
Conditions
Dravet syndromeLennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on NCT04611438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04611438.